Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended Senate Republican tax bill passes ‘SALT’ ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...